Section Arrow
TLSI.NASDAQ
- TriSalus Life Sciences
Quotes are at least 15-min delayed:2026/04/26 00:53 EDT
Regular Hours
Last
 4.64
+0.01 (+0.22%)
Day High 
4.64 
Prev. Close
4.63 
1-M High
4.8499 
Volume 
49.97K 
Bid
4.45
Ask
4.9
Day Low
4.5 
Open
4.62 
1-M Low
3.61 
Market Cap 
284.35M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 4.5 
20-SMA 4.26 
50-SMA 4.45 
52-W High 7.95 
52-W Low 3.42 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.84/-0.06
Enterprise Value
318.62M
Balance Sheet
Book Value Per Share
-0.55
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
45.15M
Operating Revenue Per Share
0.21
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ITOCiTonic Holdings Ltd.0.374+0.0744+24.83%-- 
BSXBoston Scientific Corp62.07-3.62-5.51%33.94PE
ABTAbbott Laboratories91.13-1.35-1.46%24.75PE
EWEdwards Lifesciences Corp84.15+4.43+5.56%45.45PE
PACBPacific Biosciences of California1.56-0.01-0.64%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9)agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.